Understand the source comparison
Adamax vs Semax: A Structured Comparison
Claimed origin ACTH(4-7) core + Pro-Gly-Pro tail (Met-Glu-His-Phe-Pro-Gly-Pro); documented sequence Described as ACTH(4-10)-derived melanocortin analog; commercial-product sequence not established in mainstream databases Development Institute of Molecular Gene
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Claimed origin
- ACTH(4-7) core + Pro-Gly-Pro tail (Met-Glu-His-Phe-Pro-Gly-Pro); documented sequence
- Described as ACTH(4-10)-derived melanocortin analog; commercial-product sequence not established in mainstream databases
- Development
- Institute of Molecular Genetics, Russian Academy of Sciences; decades of study
- No clear published development history under the Adamax name
- Dedicated peer-reviewed studies
- Numerous rodent studies + Russian clinical reports
- Near-absent; no robust independent trials located
- Proposed mechanism
- BDNF/NGF upregulation, TrkB signaling, anti-inflammatory/vascular, monoaminergic modulation
- Assumed identical to Semax family by association; not independently demonstrated
- Regulatory status
- Registered/marketed in Russia; NOT FDA/EU approved
- Not approved anywhere; sold research-use-only
- Human clinical data
- Yes, but Russia-specific, often small/non-randomized
- None located
- Evidence tier (overall)
- Preclinical strong + low-to-moderate clinical (Russia)
- Marketing claims extrapolated from Semax; essentially uncharacterized independently